Pfizer's Ibrance + letrozole misses general survival endpoint for metastatic breast most cancers

Spread the love

Pfizer's Ibrance + letrozole misses general survival endpoint for metastatic breast most cancers

Supply hyperlink

Leave a Reply

Your email address will not be published. Required fields are marked *